- Home
- CYH vs LYEL Comparison
CYH vs LYEL Comparison
Compare CYH & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CYH | LYEL |
|---|---|---|
| Founded | 1985 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 432.2M | 504.8M |
| IPO Year | 1991 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CYH | LYEL |
|---|---|---|
| Price | $3.44 | $25.76 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 3 |
| Target Price | $3.56 | ★ $25.00 |
| AVG Volume (30 Days) | ★ 1.9M | 89.3K |
| Earning Date | 02-18-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.47 | N/A |
| Revenue | ★ $12,644,000,000.00 | $41,000.00 |
| Revenue This Year | $0.04 | N/A |
| Revenue Next Year | $0.86 | N/A |
| P/E Ratio | $1.37 | ★ N/A |
| Revenue Growth | ★ 0.74 | N/A |
| 52 Week Low | $2.24 | $7.65 |
| 52 Week High | $4.47 | $45.00 |
Technical Indicators
Market Signals| Indicator | CYH | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 61.60 | 51.87 |
| Support Level | $3.02 | $21.95 |
| Resistance Level | $3.19 | $26.76 |
| Average True Range (ATR) | 0.17 | 2.13 |
| MACD | 0.03 | 0.18 |
| Stochastic Oscillator | 83.05 | 76.10 |
Price Performance
Historical ComparisonAbout CYH Community Health Systems Inc.
Community Health Systems Inc is a publicly owned hospital operator in the United States. The company also owns four home health agencies and provides management and consulting services to independent hospitals. The firm derives revenue through a broad range of general and specialized hospital healthcare services and outpatient services.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.